India Morning Report: It was Kotak meeting its maker again! (6250 again, naturally)

Thus the market turns south from 6320 levels though there is nothing to bother the market much.

Kotak’s mid afternoon tryst(just the 9 month report) could not shake off the market assumption that Kotak’s business is all but done and that does not bode well for it in an unbanked India Q3 results showed a grand INR 35 B in fees and INR 34.92 B in Net Interest Income yet again, not counting minute variations. Adding insult to injury, where the bank almost categorically does not expect to grow any of these businesses were the unravelling NPAs on a small portfolio

Improving NIMs at Kotak are heartening and CASA is up 22% on year. The split of the Advances column is a heartening reminder to others like Yes and Indusind evenly split across Corporate, Commercial and Retail (INR 20 B) and NIMs are much better at 4.9%

HCLT in the meantime has hooked up with CSC for Application Services Delivery centers in Bangalore and Chennai. SAP continues to explore India in the mid market Enterprise space with partner innovations. IBM recently sold Daksh back to local operators

Korean GDP releases later today will probably again reset India’s FDI expectations. Bank Policy Tuesday may appreciate the inflation correction and the increasing deposits in India’s coffers coupled with Government Borrowing turning out better than expected. Foreign Reserves are hardly comfortable but higher than usual allowing RBI to spend a couple of Dollars last week (January 5) on exchange adjustment. Bank Credit update will continue to show better growth.

HDFC , Dabur and Biocon may keep viewership glued to trading software and TV releases again. Arvind and Tech Mahindra are among the fabled Volume Breakouts of the season but we won’t be looking at them till FY16 as the model and the Distribution kinks for the former are still suspect. Aurobindo Pharma has post announcement made the splash on news count into hard stock price increases and will likely hold new levels. Biocon , if you believe in a generic thread of Indian Pharma , could still be the Indian Infy/TCS depending on your version of the morning coffee.

I am still buying IDFC and YesBank. Power NBFCs come out jst before their results break or in 2 weeks as the rest of the breakers are in town with M&M Fin joining Volume Breakouts today before earnings. CESC also sees a higher clip of returns on breakout. no Zensar isn’t making it anywhere..Lupin is still bussing up and let me know the others, it’s busy season outside the markets. 6315 was holding at 10 even with the Kiwis in trouble

Network Analysts or Gang of Analysts will do better with Lovable and Page Ind(no pun intended) as the scrips move into gear after the post ipo run meshed with a consumer rush and a dearth of supply in good stocks in 2010 . Prestige , Talwalkars and JP Associates are good for l.t. accumulation. PVR hasn’t wound down so the pie for I Sec finally broke out of the clouds and will keep growing (till it rains burgers and purple juice?)

Cymbalta apparently is a Torrent Pharma revenue which posted a good INR 10 B revenues yesterday. We haven’t captured its jumping fortunes earlier, Torrent Power sharing an equally unique business advantage in the utilities space (serving Ahd and Surat)

Davos streams on cnbc and or Bloomberg(us) could have well waited for saturday programming or the interview settings could have been suitablly upgraded from luxury breaks to business interviews for those at work

At 11am, I am shorting BOB, the 6300 calls are so cheap the 6300 straddle is the BIG WIN(Ashwini/etNOW)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s